Anne Phillips
Direttore/Membro del Consiglio presso TREVENA, INC.
Patrimonio netto: 7 287 $ in data 30/04/2024
Posizioni attive di Anne Phillips
Società | Posizione | Inizio | Fine |
---|---|---|---|
TREVENA, INC. | Direttore/Membro del Consiglio | 16/12/2014 | - |
Independent Dir/Board Member | 16/12/2014 | - | |
BARINTHUS BIOTHERAPEUTICS PLC | Direttore/Membro del Consiglio | 21/02/2021 | - |
Independent Dir/Board Member | 21/02/2021 | - | |
VTV THERAPEUTICS INC. | Direttore/Membro del Consiglio | 12/03/2024 | - |
Independent Dir/Board Member | 12/03/2024 | - | |
AMAG PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | - | - |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | 17/02/2021 | - |
Independent Dir/Board Member | 17/02/2021 | - | |
Royal College of Physicians & Surgeons of Canada
Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | Corporate Officer/Principal | - | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Direttore/Membro del Consiglio | 01/11/2022 | - |
Independent Dir/Board Member | 01/11/2022 | - |
Storia della carriera di Anne Phillips
Precedenti posizioni note di Anne Phillips
Società | Posizione | Inizio | Fine |
---|---|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Direttore Tecnico/Scientifico/R&S | 03/01/2011 | 01/08/2022 |
Consigliere Generale | 03/01/2011 | 01/08/2022 | |
AMAG PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 10/04/2019 | 16/11/2020 |
Independent Dir/Board Member | 10/04/2019 | 16/11/2020 | |
░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formazione di Anne Phillips
University of Toronto | Doctorate Degree |
University of Western Ontario | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Canada | 6 |
Regno Unito | 3 |
Posizioni
Director/Board Member | 8 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 4 |
Settori
Health Technology | 8 |
Consumer Services | 4 |
Commercial Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
TREVENA, INC. | Health Technology |
BARINTHUS BIOTHERAPEUTICS PLC | Health Technology |
VTV THERAPEUTICS INC. | Health Technology |
Aziende private | 9 |
---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Wellesley Hospital | |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Commercial Services |
Royal College of Physicians & Surgeons of Canada
Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | Consumer Services |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
St. Michael's Hospital
St. Michael's Hospital Hospital/Nursing ManagementHealth Services St. Michael's Hospital engages in the provision of healthcare services. The firm operates as a Catholic teaching and research hospital. It also offers patient care services. The company was founded in 1892 and is headquartered in Toronto, Canada. | Health Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Anne Phillips
- Esperienza